… method for monitoring CML minimal residual disease (MRD) and the optimal CML patient …
crucial aspects of CML patients molecular monitoring. Citation20 In the past years, RQ-PCR …

… the residual disease were discussed and presented, with the purpose of rapidly expanding
the importance of the molecular monitoring of … role of the molecular response was evident, the …

… the integration of molecular monitoring with other factors that affect patients’ management, …
residual disease during treatment. Measurable residual disease in chronic myeloid leukemia …

… kinase inhibitor (TKI) therapy for patients with chronic myeloid leukemia is survival, which
is … The method was used to measure residual disease in a substantial proportion of patients …

… good candidates for treatment-free remission … promising molecular approach, highly sensitive,
to monitor atypical BCR–ABL1 patients, paving the foundation to include them in treatment-…

… (MRD), defined as the presence of leukemic cells after treatment at … Molecular monitoring for
MRD is well-established in … defined disease markers, such as BCR-ABL1 in chronic myeloid …

… therapy in patients with chronic myeloid leukemia and is used to define time-related clinical
milestones as well as eligibility for stopping treatment… of residual disease in acute leukemia, …

… with the continuous improvement in the therapeutic arsenal against CML, the molecular
monitoring of CML represents the avant-garde in the struggle to make CML a curable disease. …

… A Deep Molecular Response (DMR), defined as a BCR::ABL1 … of treatment among patients
with Chronic Myeloid Leukemia (CML). However, approximately 50% of patients in Treatment-…

… We previously described TFR patients with fluctuating values of minimal residual disease
(MRD) below the threshold of MMR. In accordance with our previous definition (at least 2 …